Ahead of the market opening on Wednesday, Axis Direct picked five stocks that can generate profits in 5 to 15 days. These are ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Nagaraj Shetti, Technical Research Analyst at HDFC Securities, believes Monday's pattern could be considered as a High Wave, ...

Gilead Sciences collaborates with Indian companies to produce affordable generic versions of its HIV prevention therapy, ...

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Nifty moved in a tight range of 82 points, and ended slightly below the psychologically crucial level of 15,700. NEW DELHI: ...

Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding ...

“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic ...